FBRI and Celaid have executed a collaborative research agreement for vascular regeneration products derived from human hematopoietic stem cells

• The Foundation for Biomedical Research and Innovation at Kobe (“FBRI”) and Celaid Therapeutics Inc. (“Celaid”) have executed a collaborative research agreement.

• Under this agreement, FBRI and Celaid will conduct non-clinical in vitro and in vivo experiments to verify the angiogenic functionality of expanded human hematopoietic stem cells (HSCs). We aim to advance the research and development of vascular regeneration therapy using HSCs for delivery to patients suffering from ischemic disease (cerebral and myocardial infarction, pediatric cerebral palsy, and limb ischemia)

PRESS RELEASE（PDF）

About Foundation for Biomedical Research and Innovation at Kobe
FBRI was established in March 2000 as a core support organization for the Kobe Medical Industry Development Project, a creative reconstruction project after the Great Hanshin-Awaji Earthquake, as well as a foundation with advanced medical research functions. In April 2018, the organization was reorganized as FBRI, and is promoting its business with the goal of “disseminating solutions for a healthy society with longevity from Kobe to the world.”
*The FBRI logo is a registered trademark of the Foundation for Biomedical Research and Innovation at Kobe.

About Celaid Therapeutics Inc.
Celaid Therapeutics Inc. is a startup born out of the University of Tokyo and University of Tsukuba with proprietary technology for selective ex vivo HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapy for hematologic disease, ex vivo HSC gene therapy for genetic disorders, and angiogenesis for ischemic diseases.